Furthermore, the KEYNOTE‐18910, 11 and KEYNOTE‐40715 study demonstrated that pembrolizumab in combination with chemotherapy could improve OS versus placebo in combination with chemotherapy in nonsquamous and squamous advanced NSCLC without EGFR or ALK mutations and regardless of PD‐L1 expression, respectively. The gene discussed is ALK; the disease is non-small cell lung carcinoma.